Form 4: Sage Therapeutics CEO Barry Greene Acquires Shares Through PSU Vesting, Disposes of Shares to Cover Taxes

Sage Therapeutics CEO Barry E. Greene acquired 19,964 shares of common stock upon the vesting of Performance Restricted Stock Units (PSUs) and disposed of 4,862 shares to cover tax obligations.

Summary

• On April 10, 2025, Barry E. Greene, the President and CEO of Sage Therapeutics, acquired 19,964 shares of common stock due to the vesting of Performance Restricted Stock Units (PSUs).
• These PSUs were granted on February 11, 2022, and vested upon the achievement of certain milestones.
• Greene also disposed of 4,862 shares of common stock on the same day to satisfy tax obligations at a price of $6.91 per share.
• Following these transactions, Greene directly owns 100,169 shares of Sage Therapeutics common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The vesting of PSUs suggests the company is meeting performance goals, while the tax-related disposal is a routine event.

Positives

• The vesting of PSUs indicates the achievement of certain performance milestones by Sage Therapeutics.
• The CEO's continued stock ownership demonstrates his ongoing investment in the company's success.

Negatives

• The disposal of shares to cover tax obligations, while common, slightly reduces the CEO's overall holdings.

Risks

• Future vesting of PSUs is contingent upon achieving further performance milestones, which may not be guaranteed.
• Fluctuations in the stock price could impact the value of the CEO's holdings and potentially influence future transactions.

Future Outlook

The document does not contain specific forward-looking statements, but future Form 4 filings will likely reflect further vesting of PSUs or other transactions.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions, which are closely monitored by investors.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• The vesting of PSUs based on performance milestones is a common practice to incentivize executives to achieve specific company goals.
• Similar filings are made by executives at comparable pharmaceutical companies like Biogen, Vertex, and Amgen, reflecting similar compensation structures.

Stakeholder Impact

• Shareholders may view the vesting of PSUs as a positive sign, indicating the company is achieving its performance targets.
• The transactions have a minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Sage Therapeutics, Barry E. Greene, PSUs, Performance Restricted Stock Units, Stock Acquisition, Stock Disposal, Form 4, Beneficial Ownership, CEO